Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-Based Therapy for Acute Leukemia of Ambiguous Lineage
NCT04440267Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2020
- Primary completion
- Jun 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of vincristine, daunorubicin, cyclophosphamide, asparaginase escherichia coli, prednisone in acute leukemia of ambiguous lineage (ALAL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jul 2020; status: recruiting.
02
Drugs
vincristinedaunorubicincyclophosphamideasparaginase escherichia coliprednisone
03
Conditions
acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT04440267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440267.